Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?

Phosphodiesterase 5 inhibitors: are they cardioprotective?

A growing body of animal studies provides evidence for potential cardioprotective effects of inhibitors of the enzyme phosphodiesterase isoform 5. Infarct size reduction by administration of phosphodiesterase 5 inhibitors was described in various experimental models of ischaemia and reperfusion. Furthermore, potential beneficial effects were demonstrated in experimental models of congestive hea...

Strategic Management of Disease Covid-19

Introduction: Following the outbreak of Qovid-19, many studies have been published rapidly on research sites and scientific literature around the world. This study aimed to investigate the strategies of this epidemic. This study was conducted in a structured review method without statistical analysis that was conducted by searching related studies and resources in databases of Web of Science an...

AB030. Evolution of phosphodiesterase type 5 inhibitors

After launching of sildenafil citrate, the last invention of 20 century, in 1998, oral phosphodiesterase type 5 (PDE5) inhibitor has been established as first line treatment of erectile dysfunction and shift new paradigm of diagnosis and treatment of erectile dysfunction. The big success of sildenafil in pharmaceutical R&D induced the consecutive development of the so-called ‘The second Viagra’...

Phosphodiesterase type 5 inhibitors for erectile dysfunction.

The cyclic nucleotide signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is central to the pathophysiology of many forms of erectile dysfunction (ED), which is often associated with other chronic diseases (e.g. hypertension, type 2 diabetes mellitus) and treatments (e.g. certain drugs, radical pr...

too many students’ congresses, are they necessary and useful?